WAM
BCRX icon

Weiss Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Weiss Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-82,100
Closed -$782K – 654
2026
Q1 		$782K Buy
+82,100
New +$638K 0.01% 361

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Weiss Asset Management's BCRX Position: Q2 2026 in Review

Weiss Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 82,100 shares — an estimated $782K sold.

Weiss Asset Management first reported a position in BCRX in Q1 2026 and held it in 1 quarter. The position peaked at $782K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Weiss Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Weiss Asset Management sold 82,100 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $782K.
  • Weiss Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Weiss Asset Management's BioCryst Pharmaceuticals position peaked at $782K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Weiss Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.